OBJECTIVES:
The objective of this study was to revise the Korean Medication
Algorithm Project for
Bipolar Disorder (KMAP-BP) 2014
Children and
Adolescents.
METHODS:
We performed the
survey, using a
questionnaire comprising 22 questions according to each situation, in
children and
adolescents with
bipolar disorder.
RESULTS:
First-line pharmacotherapeutic
strategies for
manic episode in
children with
bipolar disorder were a combination of
mood stabilizer (MS) and an atypical
antipsychotics (AAP), monotherapy with an AAP,
risperidone, and
aripiprazole.
Aripiprazole was selected as first-line medication for depressive episode in
children with
bipolar disorder, and
aripiprazole, and
risperidone were selected as first-line at high-
risk children. First-line pharmacotherapeutic
strategies for
manic episode in
adolescents were a combination of MS and an AAP, monotherapy with an AAP
valproate,
lithium,
risperidone (
Treatment of Choice,
TOC),
aripiprazole, and
quetiapine. First-line pharmacotherapeutic
strategies for depressive episode in
adolescents, were a combination of an atypical
antipsychotics and
lamotrigine,
valproate,
aripiprazole (
TOC),
risperidone, and
quetiapine. For depressive episodes in
adolescents at high
risk for
bipolar disorder,
valproate,
aripiprazole (
TOC), and
risperidone were selected as first-line medication.
CONCLUSION:
We expect that the present KMAP-BP 2018-
children and
adolescents, is useful for clinicians to treat
children and
adolescents with
bipolar disorder.